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acrophages are tissue-resident innate immune cells important in homeostasis and host defense against pathogens (1) . These functionally diverse phagocytes differentiate from yolk sac-derived embryonic precursors and locally self-renew both during steady state (2-4) and helminth infection (5) . Additionally, bone marrow-derived monocytes give rise to macrophages in the intestine and the dermis (6, 7) , as well as during acute infection and inflammation (8) . However, the precise ontogeny and function of macrophages in chronic disorders, such as cancer, are incompletely understood (9) .
To investigate myeloid cells during cancer progression, we utilized the MMTV-PyMT (PyMT) mammary tumor model (10) . Myeloid cells made up more than 50% of CD45 + tumor-infiltrating leukocytes and consisted of three major populations (I, II, and III), distinguishable by morphology and cell surface expression of major histocompatibility complex class II (MHCII), CD11b, Ly6C, Ly6G, CD11c, CD115, and F4/80 ( fig. S1 ). Populations II and III phenotypically resembled Ly6C + inflammatory monocytes and neutrophils, respectively, while population I expressed classical dendritic cell (DC) markers MHCII and CD11c and the macrophage marker F4/80. Owing to the ambiguity of characterizing cell populations with surface markers (11, 12) , we sought to define these cells on the basis of transcriptional phenotype (13) . Using principal component analysis of DC and macrophage populations from the ImmGen Project (14, 15), we defined "population I" cells as tumor-associated macrophages (TAMs) because they clustered with macrophage subsets (Fig. 1A) . A support vector machine learning algorithm corroborated this classification ( fig. S2 ). Moreover, cells of population I did not express the DC lineage-specific transcription factor Zbtb46 or DC markers c-Kit, CD26, BTLA, and Flt3, but expressed the macrophage transcription factor Mafb and macrophage markers CD64 and MerTK (14, 15) (Fig. 1, B and C) . Furthermore, Flt3L-deficient PyMT mice, which lack cells of the classical DC lineage (16) , showed no defect in population I, confirming a pre-DC-independent origin of TAMs ( fig. S3 ).
Macrophages populate mammary tissues during steady state and are required for mammary gland development (17) . Upon tumor growth, we observed a decrease in the proportion of MHCII hi CD11b hi cells found in untransformed wild-type (WT) mammary glands and an increase in TAMs (Fig. 1D) . We defined MHCII hi CD11b hi cells as "mammary tissue macrophages" or "MTMs" because they also phenotypically resembled macrophages ( fig. S4 ). TAM expansion was associated with the growth of individual tumors (Fig. 1, E and F) , demonstrating that CD11b lo TAMs, but not CD11b hi MTMs, are bona fide tumor-associated macrophages that accumulate with increased tumor burden.
Tissue-resident macrophage expansion or differentiation of macrophages from blood-borne precursors could account for TAM accumulation. To distinguish between these mechanisms, we connected congenically marked PyMT mice using parabiosis ( fig. S5A ). We observed Ly6C + inflammatory monocytes, MTMs, and TAMs from both parabionts in developing tumors ( fig. S5 , B and C), demonstrating that TAMs and MTMs required input from the circulation. The chimerism of inflammatory monocytes and T cells (fig. S4, C and D) was in accordance with published studies (2, 18, 19) . This was in contrast to red pulp macrophages, which are maintained independently from monocytes (2) and consequently exhibited minimal chimerism ( fig. S5C) .
Circulating monocytes are critical progenitors for macrophages (20 PyMT mice ( Fig. 2A and fig. S6 ), implying that MTMs are constitutively repopulated by inflammatory monocytes. Owing to the loss of both the monocyte and MTM populations ( Fig. 2A and fig.  S6 ), a concomitant increase in TAMs would be expected if their maintenance was independent of CCR2 + monocytes. However, the TAM percentage in Ccr2 −/− PyMT mice was not significantly different compared to controls ( Fig. 2A and fig.  S6 ). Similar trends were observed in 20-week-old mice ( Fig. 2A and fig. S6 ), suggesting that inflammatory monocytes contribute to MTMs, and to a lesser extent, TAMs.
To determine whether inflammatory monocytes were required for TAM maintenance, we generated CCR2 DTR PyMT mice expressing diphtheria toxin receptor (DTR) under control of the Ccr2 locus (22) . DT treatment resulted in 96% depletion of tumor-associated monocytes ( Fig.  2B and fig. S7 ), compared to 80% depletion in Ccr2 −/− mice ( Fig. 2A and fig. S6 ). With this more potent depletion strategy, both MTM and TAM numbers were significantly reduced ( Fig. 2B and  fig. S7 ), suggesting that TAMs are derived from CCR2 + monocytic precursors, but require less input from the blood compared to MTMs. We considered that a higher proliferative capacity of TAMs compared to MTMs might account for their differing precursor requirement. Indeed, TAMs expressed higher levels of Ki67 staining and EdU incorporation relative to MTMs (Fig. 2 S8A ). Five and 7 days after transfer, we detected up-regulation of F4/80, CD11c, and MHCII and down-regulation of Ly6C and CD11b on the transferred cells ( Fig. 2E and fig. S8B ). Additionally, transferred cells expanded and were Ki67 + monocytes into TAMs. We performed gene-expression profiling to further distinguish TAMs from MTMs. As expected, the integrin CD11b (Itgam) was expressed at lower levels in TAMs than in MTMs (Fig. 3A) . However, several other integrins and the integrin receptor Vcam1 were up-regulated in TAMs (Fig.  3A) . "M2" or alternatively activated macrophages (AAMs) have been proposed to be associated with tumor progression (24) . Surprisingly, we found that the TAM population did not express AAM markers such as Ym1, Fizz1, and Mrc1; instead, MTMs more closely resembled AAMs ( Fig. 3A and fig. S10 ). In line with the expression data, Vcam1 and Mrc1 (CD206) proteins were detected in TAMs and MTMs, respectively (Fig. 3B ). Combining these markers with our monocyte transfer system, we addressed whether TAMs differentiated from MTMs. The lack of Mrc1 expression on transferred monocytes at all examined time points suggested that TAM differentiation from monocytes was a distinct pathway, rather than MTM conversion (Fig. 3C) . Additionally, we detected Vcam1 up-regulation on TAMs as a late differentiation event (Fig. 3C) . Altogether, we identified sequential phenotypic changes in monocytes during TAM differentiation ( fig. S11 ).
The finding that TAMs did not resemble AAMs was unexpected, because the type 2 cytokine interleukin-4 (IL-4) produced by T cells and/or tumor cells has been implicated in TAM polarization (25, 26) . Additionally, in other M2-polarizing environments, IL-4 is crucial for the expansion of tissue-resident macrophage populations (5 (Fig. 1D) 
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fl/fl PyMT mice had reduced tumor burden (Fig. 4C) . In Ccr2 −/− PyMT mice, Fig. 2A and fig. S6 ), tumor development was unaffected ( fig. S17A) , implying a nonredundant function for RBPJdependent TAMs in promoting tumor growth. In the PyMT model, CD11c
+ myeloid cells act as antigen-presenting cells, forming stable, yet unproductive, interactions with tumor-infiltrating T cells (12) . We hypothesized that one tumorpromoting function of TAMs may be their control of the adaptive immune response. Granzyme B (GzmB) is a cytolytic molecule important for tumor immunosurveillance. Conversely, Programmed Death-1 (PD-1) is an inhibitory co-receptor denoting "exhausted" T cells. As PyMT tumors progressed, an increase in PD-1 + GzmB -
CD8
+ T cells was observed (Fig. 4D) , paralleling TAM expansion, with PD-1 + cells making up~50% of latestage tumor-infiltrating CD8 + T cells (Fig. 4E) . In CD11c cre Rbpj fl/fl PyMT mice, the PD-1 + population decreased, whereas the GzmB + population increased (Fig. 4, F and G) . In contrast, the T cell phenotype in Ccr2 −/− mice was unchanged (fig.
S17, B to D). Classical DCs also delete RBPJ in the CD11c
cre Rbpj fl/fl system, so we examined Flt3L-deficient PyMT mice that lack cells of the DC lineage, but have a comparable TAM population ( fig. S3 ). Flt3l −/− PyMT mice showed no difference in tumor growth or CD8 + T cell phenotype ( fig. S17, E to H) . These data suggest a specific function for RBPJ-dependent TAMs in promoting tumor immune tolerance in part by modulating the CD8 + T cell response ( fig. S18 ). Other RBPJ-dependent TAM functions, including nonimmune regulatory roles, require further investigation. In addition, TAM differentiation is not completely abolished in the absence of RBPJ, raising the possibility that the remaining TAM intermediates may have tumor-promoting activities. Furthermore, to what extent TAM differentiation from monocytes occurs in other murine and in human tumors remains to be determined. Nonetheless, our findings suggest that a better understanding of this distinct tumor-elicited inflammatory response may create new opportunities for cancer treatment. Student's t test was performed and statistical significance is indicated by **P < 0.01. 
